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Ubiquitin (Ub) ligation by the action of E1-E2-E3 enzyme cascades 
is a widespread mechanism that controls protein function. After 
E1-mediated formation of a transient, thioester-bonded E2~Ub 
intermediate, E3s promote Ub ligation to specific protein substrates 
(“~” denotes covalent complex; “−”, noncovalent complex). The 600 
predicted members of the largest human E3 family contain a RING 
domain that binds and activates an E2~Ub intermediate to ligate Ub to 
a substrate recruited to a distal protein-interaction domain1. APC/C 
is a behemoth ~1.5 MDa E3 that controls cell division by promoting 
timely Ub-mediated proteolysis of key regulatory proteins. Human 
APC/C has at least 14 core subunits (APC1, APC2, APC3 (CDC27), 
APC4, APC5, APC6 (CDC16), APC7, APC8 (CDC23), APC10 
(DOC1), APC11, APC13, APC15, APC16 and CDC26), several of 
which are present in duplicate in each holo APC/C enzyme2,3. APC/C 
is activated at different stages of the mitotic cell cycle by association 
with either CDC20 or CDH1, which target proteins for ubiquitina-
tion by binding substrate KEN-box motifs directly and recruiting 
substrate D-box sequences in collaboration with APC10 (refs. 4–7). 
To prevent chromosome segregation defects such as aneuploidy, 
CDC20 assembles with MAD2, MAD3 (BUBR1) and BUB3 to form 
a mitotic checkpoint complex (MCC) that binds and inhibits APC/C 
until all chromosomes are properly bioriented on the mitotic spin-
dle8,9. MCC serves as a decoy KEN-box–based substrate–receptor 
complex, which blocks APC/C association with free CDC20 and bona 
fide KEN- and D-box–containing substrates5,10.
Following MCC disassembly, APC/C associates with free CDC20 to 
promote Ub-mediated proteolysis of substrates such as cyclin B and 
securin to initiate chromosome segregation. Subsequently, APC/C asso-
ciates with CDH1 to regulate exit from mitosis and during G1 to promote 
Ub-mediated turnover of regulators of the G1-S transition and DNA 
replication. In higher eukaryotes, APC/CCDH1 is restrained during inter-
phase by the distinctive EMI1 (Rca1 in Drosophila)11–14. APC/C inhibi-
tion by EMI1 allows accumulation of substrates such as mitotic cyclins 
and geminin11,15–17. EMI1 also functions later in a localized manner, 
inhibiting APC/CCDH1-mediated ubiquitination of cyclin B at spindle 
poles18. Misregulation of EMI1 leads to endoreduplication and mitotic 
defects such as abnormal spindles and excess centrosomes14,16,17,19,20.
EMI1 has three domains. The N-terminal domain mediates reg-
ulatory interactions that control localization and EMI1’s own sta-
bility18,21. An F-box binds SKP1 but to date has not been shown to 
function in APC/C inhibition12,19. The C-terminal domain is respon-
sible for APC/C inhibition and contains a D-box, linker sequence, 
a zinc-binding region (ZBR) and a C-terminal tail12,22. Previous 
reports concluded that the EMI1 C-terminal domain is a pseudo-
substrate inhibitor that binds to CDH1 and competes in a D-box– and 
ZBR-dependent manner with the substrate cyclin B for binding to 
APC/CCDH1 (refs. 12,22). However, studies of the homologous meiotic 
APC/C inhibitor EMI2 suggested that a key inhibitory region is the 
C-terminal tail23,24. Despite its importance, structural mechanisms 
by which EMI1 inhibits APC/CCDH1 are unknown.
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To understand EMI1-mediated inhibition of APC/C, we performed 
a hybrid structural analysis. NMR studies indicated that other than the 
45-residue ZBR, the 143-residue C-terminal EMI1 inhibitory region 
lacks fixed tertiary structure. Electron microscopy (EM) studies 
revealed that EMI1 interacts with, approaches and/or alters the 
conformations of numerous subunits of the ~1.5 MDa APC/CCDH1 
molecular machine. The functional importance of intrinsic structural 
disorder is explained by the D-box, linker, ZBR and tail synergistically 




To guide structural studies, we analyzed the human EMI1 protein 
sequence with the program PONDR (http://www.pondr.com/index) 
to identify folded domains25. The majority of EMI1 is predicted to 
be intrinsically disordered, with the exception of a short N-terminal 
region, the F-box and the ZBR (Fig. 1a). In the APC/C-inhibitory C-
terminal domain, regions predicted to be unstructured include the 
D-box, linker region and tail. To test this hypothesis, we character-
ized structural properties for the EMI1 C-terminal domain (hereaf-
ter referred to as EMI1DLZT for D-box, linker, ZBR, tail) by NMR. 
Backbone resonance assignments revealed that the chemical shifts 
were consistently dispersed for the ZBR residues in the EMI1DLZT, 
EMI1ZT and EMI1Z constructs, indicating that the ZBR is an autono-
mously folded domain (Fig. 1b). Notably, the remaining resonances 
in EMI1DLZT displayed poor dispersion, low or negative {1H}-15N 
heteronuclear NOE (HetNOE) values and relatively low differences 
in Cα chemical shifts compared with values predicted for a random 
coil (Fig. 1c).
Figure 1 The APC/C inhibitory domain of EMI1 contains two intrinsically disordered segments separated  
by a zinc-dependent folded domain. (a) Output of structure prediction program PONDR, with schematic  
views of EMI1 structural elements shown above. F, F-box–SKP1; D, D-box; L, linker; Z, zinc-binding  
region; T, tail. (b) Overlay of 15N-1H HSQC spectra of uniformly 15N-labeled EMI1DLZT (blue, consisting  
of the DLZT, corresponding to the APC/CCDH1 inhibitory domain12,22), with EMI1ZT (red) or EMI1Z (green)  
superimposition showing dispersal of peaks found in the isolated EMI1Z domain. A subset of disperse  
resonances assigned for EMI1DLZT are labeled. (c) Heteronuclear NOE data and difference in Cα chemical  
shifts (measured value to predicted value for random coil50) for uniformly 15N-labeled EMI1DLZT measured at  
25 °C. Similar results obtained at 5 °C are not shown. (d) Overlay of 15N-1H HSQC spectrum of EMI1ZT (red) with  
that after treatment with EDTA (black) on left and after subsequent reconstitution with zinc (blue) on right. (e) One-dimensional proton NMR spectra 
for EMI1ZT or the indicated cysteine mutants. (f) Dynamic light scattering data (DynaPro Nanostar) and fit for hydrodynamic radius (Dynamics V7.1.7 
software, Wyatt) for EMI1DLZT. (g) Analytical ultracentrifugation data showing sedimentation coefficient distribution (c(s)) analysis for determination of 
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Previous studies showed that mutation 
of ZBR cysteines or treatment with a metal 
chelator decreased EMI1’s competition with 
substrate binding or inhibition of substrate 
ubiquitination by APC/C19,22. We found that 
the addition of a metal chelator, EDTA, to 
15N-labeled EMI1ZT eliminated the 15N-1H chemical shift dispersion 
that is characteristic of the folded structure, which was re-established 
by ZnSO4 addition (Fig. 1d). To resolve the ambiguity of one poten-
tial zinc-coordinating residue19, we ascertained that mutation of 
Cys409, but not Cys411, eliminated the hallmarks of folding in one- 
dimensional proton NMR spectra (Fig. 1e).
To further characterize the biophysical properties of EMI1DLZT, 
we measured the hydrodynamic radius (Rh) to be 3.1 nm and 
2.9 nm by dynamic light scattering (DLS) and analytical ultracen-
trifugation, respectively (Fig. 1f,g). A globular protein would have 
to be ~46 kDa, rather than the 16.0 kDa of EMI1DLZT, to yield an 
Rh value of 3.1 nm by DLS. The best-fit, weight-average anhydrous 
frictional ratio (f/f0)w values of 1.73 and 1.85 obtained from two 
analytical ultracentrifugation experiments indicate that EMI1DLZT 
is elongated in solution (Supplementary Fig. 1). Overall, the data 
suggest that EMI1DLZT is substantially intrinsically unfolded, with 
predominantly disordered D-box, linker and tail regions separated 
by a folded ZBR.
EM reveals multisite EMI1 binding to APC/CCDH1
Previous EM studies revealed a structurally dynamic triangular 
APC/C architecture organized from three superdomains: (i) an ‘arc 
lamp’ comprising TPR subunits APC7, APC3, APC6 and APC8 and 
associated small subunits APC16, APC13 and CDC26; (ii) a ‘platform’ 
comprising APC1, APC4, APC5 and APC15; and (iii) a catalytic 
core, located between the arc lamp and platform, containing the 
APC2-APC11 cullin–RING complex and the substrate co-receptor, 
APC10 (ref. 6,10). These superdomains surround a large central 
cavity containing the substrate-binding site and proposed catalytic 
site26. Different conformers were observed for apo-APC/C, which 
vary in relative positions for the arc lamp and platform, reflecting 
the dynamic nature of the complex10. CDH1 binds APC3 in the arc 
lamp, with its substrate-binding WD40 domain projecting toward 
the catalytic core27.
To understand the structural basis for inhibition, we performed 
a series of single-particle reconstructions by negative-stain EM on 
complexes between APC/C purified from HeLa cells reconstituted 
with CDH1 and various versions of EMI1. Versions of EMI1 contain-
ing an F-box were complexed with SKP1. In comparison to human 
APC/CCDH1 (ref. 6), the APC/CCDH1–EMI1–SKP1 complex displays 
additional prominent density, which we attribute to EMI1–SKP1 
(Fig. 2a and Supplementary Fig. 2a,b). EMI1–SKP1 occupies and 
thus occludes access to the entire central cavity of APC/C. One edge 
of EMI1–SKP1 approaches the base of the arc lamp and the CDH1 
WD40 domain. The other side is contiguous and integrated with 
the platform.
EM analysis further reveals that despite its small size, the inhibi-
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Figure 2 EM structures of APC/CCDH1 inhibited 
by EMI1–SKP1 and the inhibitory C-terminal 
domain (EMI1DLZT). (a) Three views of human 
APC/CCDH1–EMI1–SKP1, showing the structural 
superdomains of APC/C (arc lamp, platform  
and catalytic core) and the CDH1 and APC10 
D-box co-receptors. The density attributed 
to EMI1–SKP1 is outlined. (b) Three views 
of human APC/CCDH1–EMI1DLZT, showing the 
structural superdomains of APC/C (arc lamp, 
platform and catalytic core) and the CDH1 
and APC10 D-box co-receptors. The density 



































































































Figure 3 EMI1 is a tight binding inhibitor of APC/C Ub ligation and Ub-chain formation. (a) Fluorescence detection of cycB-NT* ubiquitination by  
APC/CCDH1 with UBCH10, alone or in combination with UBE2S, in the absence or presence of EMI1–SKP1 or EMI1DLZT. (b) Fluorescence detection of  
APC/C-dependent UbcycB-NT* ubiquitination by UBE2S in the absence of UBCH10 and in the absence or presence of CDH1. The K0UbcycB-NT* 
substrate has all lysines in the Ub moiety mutated to arginines. (c) Sequence alignment of the EMI1 D-box region with EMI1 and Hsl1 D-box peptides. 
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activity (Fig. 2b and Supplementary Fig. 2c). 
For the complexes with both EMI1–SKP1 and 
EMI1DLZT, there are differences in the vicinity 
of the D-box co-receptors CDH1 and APC10 
and additional density linking this region 
and the catalytic core and platform regions. 
Substantial additional density is also observed 
emanating from the platform. Notably, rela-
tive to prior apo-APC/C and APC/CCDH1 
structures, in both EMI1-inhibited complexes 
the catalytic core forms a prominent contact 
with platform regions assigned to APC1 and 
APC4, which are repositioned. The density 
assigned to APC1 and APC4 has lost contact 
with APC5, is no longer in the position pre-
viously observed for apo-APC/C26,27 and is 
instead bent toward the catalytic core.
A difference map comparing the full APC/CCDH1–EMI1–SKP1 
complex with APC/CCDH1–EMI1DLZT reveals additional exposed 
density more distal from the APC/C central cavity and catalytic 
core, which we attribute to the N-terminal domain and SKP1-bound 
F-box (Supplementary Fig. 2d). This agrees with the location of 
extra density for a complex harboring a maltose-binding protein 
fused at the N terminus of SKP1 (Supplementary Fig. 2e).
Tight-binding inhibition of substrate ubiquitination
APC/CCDH1 utilizes a two-step mechanism to mediate substrate 
polyubiquitination28. First, APC11 activates Ub transfer from an E2 
(often UBCH10 in human cells) directly to the substrate29–32. Second, 
another E2 (UBE2S in humans32–35) transfers Ub to a substrate-ligated 
Ub to mediate chain elongation28,36.
Because of the large quantities of APC/C required to dissect mecha-
nisms underlying EMI1-mediated inhibition, we turned to a recombinant 
APC/C system37. The hallmark features of endogenous human APC/C 
were recapitulated in our assays using a fluorescently tagged cyclin B N-
terminal domain (cycB-NT*) as the substrate: ubiquitination depends 
on APC/C and CDH1, with low-molecular-weight products being 
formed by UBCH10, high-molecular-weight (HMW) products being 
formed by UBCH10 and UBE2S together, and inhibition being pro-
duced by EMI1–SKP1 and EMI1DLZT (Fig. 3a). This prompted us to 
develop assays to separately investigate APC/C-mediated ubiquitina-
tion with the two E2s. We were able to quantify APC/CCDH1–UBCH10–
 mediated ubiquitination of both cycB-NT* and a fluorescent Ub fusion 
(UbcycB-NT*), which is also a substrate for APC/CCDH1–UBE2S–
 mediated ubiquitination even in the absence of UBCH10 (Fig. 3b).
We first performed a series of titrations to determine the saturat-
ing concentrations of CDH1 and identify conditions in which the 
ubiquitination reactions were in initial rate regimes (Supplementary 
Figs. 3–5). Subsequent titrations of UBCH10, UBE2S and substrate 
allowed measurement of Km values (Supplementary Fig. 3d). The Km 
of 290 ± 80 nM for cycB-NT* in reactions with UBCH10 closely agrees 




UBCH10 UBCH10 UBE2S No CDH1, UBE2S No CDH1, UBE2S
cycB-NT* UbcycB-NT* UbcycB-NT* UbcycB-NT* Ub*
Ki app (nM) Ki app (nM) Ki app (nM) Ki app (nM) Ki app (nM)
EMI1–SKP1 ≤2.5 ≤2.5 ≤2.5 690 ± 130 230 ± 35
EMI1FDLZT ≤2.5 ≤2.5 ≤2.5 NT NT
EMI1DLZT ≤2.5 ≤2.5 ≤2.5 NT NT
EMI1D(Mut)LZT >10,000 >10,000 810 ± 230 NT 220 ± 37
EMI1NFDLZ 440 ± 60 360 ± 47 940 ± 220 NT >6,000
EMI1NFDL 510 ± 120 330 ± 74 1,500 ± 340 NT NT
EMI1ZT >10,000 >10,000 520 ± 86 NT 2,000 ± 400
EMI1Z >80,000 >80,000 >80,000 NT >80,000
EMI1T >1 mMa >1 mMa 42,000 ± 12,000 48,000 ± 12,000 13,000 ± 2,400
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Figure 4 EMI1DLZT elements synergize to mediate optimal inhibition. (a) Localization of 
EMI1 linker and C terminus. A WD40 propeller was inserted into the linker and at the  
C terminus of EMI1FDLZT in complex with SKP1. The three-dimensional structures 
calculated contained additional densities based on the calculation of difference density 
maps, although the extra densities do not fully occupy the expected volume for a propeller, 
probably because of flexible connections. Shown are the strongest peaks in the difference 
maps for the linker insertion in blue and the C-terminal insertion in purple, relative to APC/
CCDH1–EMI1–SKP1. Conformational variability was distinguished from additional densities 
by the fact that negative and positive difference densities are located next to each other in 
areas with substantial conformational flexibility, whereas no negative difference density can 
be observed for the WD40 propeller insertions. (b) Human APC/CCDH1–EMI1DLZT, showing 
density attributed to the D-box and associated CDH1 in yellow, to the linker in green and 
to the ZBR and tail integrated with portions of APC1 and APC4 in purple. (c) Sequence 
alignment of the EMI1 D-box and linker region indicating mutations. (d) Fluorescence 
detection of APC/CCDH1- and UBCH10-dependent cycB-NT* ubiquitination either in the 
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with previous measurements of 228 and 63 nM for similar substrates 
with immunopurified endogenous Xenopus laevis and Saccharomyces 
cerevisiae APC/C, respectively38,39.
Experiments with EMI1–SKP1 revealed tight binding inhibition, 
which we quantified using the Morrison equation40. Performing 
experiments under initial rate conditions required our use of 5 nM 
APC/CCDH1, for which the tight binding nature of EMI1 and data 
quality at the stoichiometric point (1:1 APC/CCDH1:EMI1) restricted 
our accurate quantification of apparent Ki (Kiapp) values to a lower 
limit of 2.5 nM (Supplementary Fig. 5d). Titration of EMI1–SKP1 
revealed Kiapp values of ≤2.5 nM, and potentially substantially 
lower, for APC/CCDH1-mediated substrate ubiquitination with 
both UBCH10 and UBE2S, as approximately 5 nM of EMI1–SKP1 
completely inhibits these reactions (Table 1). Similar results were 
obtained for a version lacking the EMI1 N terminus or the entire 
N-terminal domain and F-box–SKP1, which consisted exclusively of the 
C-terminal D-box, linker, ZBR and tail regions. Below we describe 
how the distinct elements within EMI1DLZT contribute to a tight 
binding mode of APC/CCDH1 inhibition.
EMI1 has an essential but relatively weak D-box
An obvious key functional element is EMI1’s D-box. In examin-
ing the EM data, there were differences between APC/CCDH1 and 
the EMI1–SKP1– and EMI1DLZT-bound complexes in the vicinity 
of CDH1 and APC10, consistent with EMI1’s D-box binding the 
co-receptors (Supplementary Fig. 2). We were unable to gener-
ate stoichiometric complexes for mutants lacking EMI1’s D-box. 
Furthermore, alanine substitutions in place of Arg322 and Leu325 
in EMI1DLZT’s D-box RxxL motif decreased inhibition of cycB-NT* 
in reactions with UBCH10 to the point that we could not measure 
a Ki under the initial rate conditions (Table 1). The Kiapp increased 
by over two orders of magnitude for UbcycB-NT* ubiquitination by 
APC/CCDH1 and UBE2S.
Despite its requirement, the EMI1 D-box on its own is relatively 
weak: an isolated EMI1D peptide is insufficient as an inhibitor even 
at the 100 µM concentration we could achieve in our assays. This 
contrasts with an isolated D-box peptide from the S. cerevisiae APC/C 
substrate Hsl1 (ref. 41), which is a more potent inhibitor (Fig. 3c,d).
EMI1 elements synergize to inhibit substrate ubiquitination
In order to map the locations of the remaining portions of EMI1, 
we generated single-particle EM reconstructions for mutants in 
EMI1FDLZT–SKP1 with insertions between residues 354 and 355 
in the linker upstream of the ZBR and at the C terminus of EMI1 
(Fig. 4a). In this latter case, it was necessary to replace the EMI1 
D-box with that from Hsl1 to enhance complex formation. The inser-
tions contained the β-propeller from S. cerevisiae Doa1, which has 
N and C termini in close proximity42. Although we cannot be certain 
that the insertions do not alter native interactions, the data are consist-
ent with the linker projecting away from the D-box bound to CDH1 
and APC10 and toward the APC/C platform and catalytic core and 
with the ZBR and tail extending across the platform (Fig. 4a,b).
Prompted by the structural data showing that an insertion maps 
to the central location between the D-box co-receptor APC10, the 
Figure 5 NMR structure of the ZBR and 
identification of a surface required for 
inhibition. (a) Solution structure of the  
ZBR portion of EMI1ZT as cartoon with zincs as 
spheres on left, and as ribbons superimposed 
with the RNF31 (PDB 2CT7, gold) IBR on 
right. (b) The crystal structure of the EMI1 
ZBR is shown with approximate location next 
to the EM structure of APC/CCDH1–EMI1DLZT 
at the same scale. (c) Alanine scan testing 
roles of indicated ZBR side chains on 
EMI1DZLT-mediated inhibition of cycB-NT* 
ubiquitination by APC/CCDH1 and UBCH10. 
Inhibition by wild-type EMI1DLZT and 
EMI1NFDL–SKP1 (lacking the ZBR and tail)  
are shown for comparison. (X) denotes 
unfolded mutants. Mutants displaying the 
greatest decrease in inhibitory activity 
are marked with purple dots; those with a 
lesser decrease in inhibitory activity are 
marked with gold dots. (d) Comparison of 
the effects of the indicated surface alanine 
mutants and the unfolding C409A mutant on 
EMI1DZLT-mediated inhibition of cycB-NT* 
ubiquitination by APC/CCDH1 and UBCH10.  
(e) Structure of EMI1 ZBR showing all side 
chains mutated in alanine scan as sticks, 
with those causing the greatest decrease 
in inhibitory activity in purple and a lesser 
decrease in inhibitory activity in gold.  
(f) Location of Ser383 (side chain shown 
as green stick with oxygen in red) cyclin-
dependent kinase–mediated phosphorylation 
site on cartoon representation of EMIZT 
structure with the two zinc atoms shown as 
spheres, the sites of Ala mutations that impair EMI1DLZT-mediated inhibition colored as in panel e. Ser383 is among three cyclin-dependent kinase 
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arc lamp and the platform (Fig. 4a), we considered that the linker 
might be functionally important. Indeed, the linker is not simply a 
spatial connector joining the D-box and ZBR effectors: deleting 20 
linker residues impairs EMI1DLZT-mediated inhibition, which is not 
restored by replacing them with a 20-residue, glycine-rich sequence 
(Fig. 4c,d). As a first attempt to address whether this sequence or 
structure may be important, we tested two 10-residue deletions and 
found only one to cause severely impaired inhibition. Triply mutating 
conserved Leu345, Tyr356 and Arg358 within the essential sequence 
to alanines, either in the context of the benign 10-residue deletion or 
in EMI1DLZT, was sufficient to substantially impair inhibition. Thus, spe-
cific side chains within the linker contribute to inhibition (Fig. 4d).
One reason the linker or other C-terminal elements may be impor-
tant would be to compensate for EMI1’s relatively weak D-box. 
Inhibitory roles of regions other than the D-box are reflected by the 
D-box–mutated version of EMI1D(Mut)LZT inhibiting formation of 
HMW conjugates after extended reaction times with UBCH10 despite 
causing no measurable inhibition under initial rate conditions (Fig. 4d, 
Table 1 and Supplementary Fig. 6). In contrast, grafting the Hsl1 
‘Super’D-box into EMI1DLZT largely overcame the defects resulting 
from deleting the linker, even in combination with the ZBR-unfolding 
C409A mutation (Fig. 4d). Thus, it appears that EMI1’s weak but 
essential D-box must function combinatorially with additional ele-
ments for optimal inhibition. C-terminal deletions, which retained 
the D-box and linker (EMI1FDLZ and EMI1FDL) but lacked the tail or 
both the ZBR and tail, inhibited the reactions with both E2-substrate 
pairs, with Kiapp values increased by more than two orders of mag-
nitude. Notably, deleting the ZBR had little effect in the absence of 
the EMI1 C-terminal tail; this underscores the importance of the tail 
in functioning with the D-box and/or linker to maximally inhibit 
APC/CCDH1 activity with both E2s (Table 1). Taken together, the data 
suggest that the D-box, linker, ZBR and tail bind multiple sites on 
APC/CCDH1 to synergistically antagonize ubiquitination activity.
NMR structure and inhibitory surface of the EMI1 ZBR
To gain insights into potential contributions of the ZBR in APC/C 
inhibition, we assigned backbone and side-chain resonances of 13C, 
15N-labeled EMI1ZT and determined the solution structure (Fig. 5a,b 
and Table 2). Although the EMI1ZT construct spans residues 363–447, 
only residues 375–420 exhibited the features of a folded domain, with 
a central, twisted, four-stranded β-sheet and two zinc ions on opposite 
ends of the sheet. One zinc is chelated by the β1-β2 and β3-β4 loops, 
and the other by the β2-β3 loop and a loop following β4. The ZBR 
displays an In-Between-RING (IBR) domain topology, aligning with 
the IBR of RNF31 with 5.5 Å r.m.s. deviation.
The NMR structure enabled identification of a functionally 
important surface on the ZBR through alanine-scanning mutagen-
esis of EMI1DLZT. Under conditions in which APC/CCDH1 is insen-
sitive to a version of EMI1 lacking the ZBR and tail (EMI1NFDL) 
but is inhibited by wild-type EMI1DLZT, several mutants impaired 
EMI1DLZT-mediated inhibition of APC/CCDH1 ubiquitination with 
either UBCH10 or UBE2S (not shown) (Fig. 5c,d). The majority of 
defective mutants (L375A, K376A, R380A N382A, K386 D388A, 
Y387A, P384A) mapped to a single surface (Fig. 5e,f). The diminished 
inhibition caused by the three most deleterious individual alanine 
mutants—at positions Leu375, Lys376 and Arg393—resembled that 
caused by unfolding the ZBR through mutation of the Cys409 zinc 
ligand (Fig. 5d). Although we found the R393A mutant to also be 
unfolded, NMR analysis of 15N-labeled samples confirmed folding 
of the L375A and K376A mutants (Supplementary Fig. 7), suggest-
ing that the ZBR is not solely a structured tether between the linker 
and tail. Rather, the surface harboring these residues is important 
for inhibition. Leu375 and Lys376 are at the N terminus of the ZBR 
domain, suggesting spatial proximity between the inhibitory ZBR 
surface and the upstream linker sequence in EMI1.
ZBR and C-terminal tail synergize to block chain elongation
A distinctive pattern of inhibition was observed for the EMI1 frag-
ment consisting only of the ZBR and tail, which on its own inhib-
ited APC/CCDH1–UBE2S–mediated ubiquitination of UbcycB-NT*, 
although relatively weakly, with a Kiapp of 520 nM (Table 1). The 
ZBR and tail synergize, as we could not measure inhibition with 
the isolated ZBR at the highest concentration we could achieve, 
and the Kiapp increased to 42 µM for a synthetic peptide corresponding 
to the isolated EMI1T. We did not observe obvious effects of EMI1ZT 
on the initial rate of Ub ligation by UBCH10 (Table 1).
Because the EM data indicated that the EMI1ZT region interacts with 
the APC/C catalytic core and/or platform regions (Fig. 4a), we tested 
whether EMI1ZT inhibits APC/CCDH1–UBE2S–mediated Ub ligation 
independently of counteracting substrates recruited to the distal 
D-box binding site. Even though UBE2S binds coactivator proteins34,43 
and generates Ub chains even in the absence of an E3 (ref. 44), we 
identified conditions in which APC/C stimulated UBE2S-mediated 
ubiquitination of UbcycB-NT* even in the absence of CDH1 (Fig. 3b 
and Fig. 6a). Although the Ki for full-length EMI1 increased substan-
tially, presumably due to lack of its D-box recruitment by CDH1, the 
isolated EMI1T inhibited APC/C–UBE2S–mediated ubiquitination 
of UbcycB-NT* equally well in the presence or absence of CDH1 
(Table 1 and Fig. 6a,b).
Table 2 NMR and refinement statistics
Protein
NMR distance and dihedral constraints
Distance constraints
 Total NOE 931
 Intra-residue 381
 Inter-residue
  Sequential (|i – j | = 1) 211
  Medium range (|i – j | < 4) 83
  Long range (|i – j | > 5) 256
  Intermolecular 8
 Hydrogen bonds 32




Violations (mean ± s.d.)
 Distance constraints (Å) 0.0093 ± 0.001
 Dihedral angle constraints (°) 0.1833 ± 0.061
 Max. dihedral angle violation (°) 0.8600 ± 0.300
 Max. distance constraint violation (Å) 0.2100 ± 0.060
Deviations from idealized geometry
 Bond lengths (Å) 0.0
 Bond angles (°) 0.0
 Impropers (°) 0.015
Average pairwise r.m.s. deviation (Å)a
 Heavy 0.554
 Backbone 0.954
aBackbone and heavy atom r.m.s. deviations were calculated by superimposing residues 
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The indifference to CDH1 implied that 
the isolated EMI1T targets a catalytic func-
tion of APC/C–UBE2S independently of 
blocking APC/C binding to a D-box sub-
strate. We developed an assay for APC/C- 
and UBE2S-dependent synthesis of di-Ub 
chains, using as a substrate a Ub variant labeled with fluorescein 
on a C-terminal cysteine (Fig. 6c,d). Full-length EMI1 remained 
a superior inhibitor, with an order-of-magnitude lower Kiapp 
than that measured for EMI1ZT even for this substrate-independ-
ent Ub chain formation, suggesting that the structurally observed 
multisite APC/C binding enhances EMI1 inhibition of catalysis. 
Full-length EMI1 and EMI1D(Mut)LZT displayed similar degrees of 
inhibition, consistent with the notion that the D-box is recruited 
to CDH1. Inhibitory effects of EMI1ZT, EMI1Z and EMI1T roughly 
paralleled those observed in CDH1-dependent ubiquitination of 
UbcycB-NT* (Table 1). Thus, EMI1T inhibits APC/C–UBE2S– 
catalyzed Ub-chain formation. Furthermore, this appears to be the 
case even in assays containing both UBE2S and UBCH10, as upon 
adding high concentrations of the shorter EMI1ZT, we observed a 
selective decrease in the HMW products corresponding to those 
generated when UBE2S was included in the reactions (Fig. 6e). 
Comparing EMI1 and UBE2S sequences provides a rationale for the 
E2 selectivity, as the conserved residues in their C-terminal sequences 
are identical (Fig. 6f). Previous studies showed that the unique UBE2S 
C-terminal sequence is essential for APC/C recruitment34,35.
DISCUSSION
At a global level, EMI1 shares some features with the other APC/C 
inhibitor, MCC. Both occupy the APC/C central cavity, on one 
end mimicking bound substrate and on the other binding and 
structurally reorganizing the platform to lock APC/C in a closed 
state (Supplementary Fig. 8)5,45,46. However, whereas the MCC is 
~200 kDa and includes CDC20, APC/C is shut down by only a 
143-residue C-terminal inhibitory domain from EMI1. Importantly, 
EMI1 is a distinct entity from CDH1, explaining how EMI1 can bind 
to APC/C already assembled with CDH1. Furthermore, between the 
EM data showing EMI1 contacting the APC/C catalytic core and 
biochemical data analyzing reactions inhibited by EMI1, we also 
uncovered a function for the unstructured C-terminal tail of EMI1 
in blocking catalysis of Ub-chain elongation by UBE2S. As both EMI1 
and UBE2S are found only in higher eukaryotes, this selective antago-
nism and the similar C-terminal sequences may reflect more recent 
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Figure 6 The EMI1 C-terminal tail is a specific 
inhibitor of APC/C- and UBE2S-dependent 
ubiquitin-chain formation. (a,b) Representative 
fluorescence scan of raw SDS-PAGE data (a)  
and curve fit (b) for inhibition of APC/C-
dependent, CDH1-independent ubiquitination 
of UbcycB-NT* in the presence of increasing 
concentrations of a peptide corresponding to the 
EMI1 C-terminal tail (EMI1T). Standard error 
of the mean (SEM), n = 3. (c,d) Representative 
fluorescence scan of raw SDS-PAGE data (c) and 
curve fit (d) for inhibition of APC/C-dependent, 
CDH1-independent ubiquitination of Ub* in  
the presence of increasing concentrations  
of a peptide corresponding to EMI1T. SEM,  
n = 3. (e) Fluorescence detection of cycB-NT*  
ubiquitination by APC/CCDH1 by UBCH10 
and UBE2S in the absence or presence of 
EMI1DLZT or increasing amounts of EMI1ZT. 
EMI1ZT selectively inhibits formation of HMW 
conjugates formed when UBE2S is included in 
the reaction. (f) Alignment of EMI1 C-terminal 
sequences from the indicated organisms and  
the corresponding region of human EMI2  




















Figure 7 Mechanisms of APC/C inhibition model for EMI1 inhibition of 
APC/CCDH1. EMI1’s inhibitory C-terminal domain binds multiple sites 
for multimodal inhibition of APC/CCDH1, blocking both substrate access 
to the D-box co-receptors CDH1 and APC10 and preventing Ub-chain 
elongation by UBE2S. The N-terminal domain of EMI1 is exposed, 
enabling regulation by binding to other partner proteins that modulate 
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Alternatively, a key EMI1 function may be to block Ub-chain elonga-
tion. UBE2S is apparently required for normal mitosis only in a subset 
of cell types but in other cells may be important for recovery from 
the spindle checkpoint33,34. UBE2S-mediated Ub-chain elongation is 
thought to be particularly important for substrates with few lysines 
serving as sites of initial Ub ligation and may also be important for 
substrates whose turnover is regulated by deubiquitinating enzymes32. 
Thus, by extension, such substrates might also be especially sensitive 
to regulation by EMI1.
Notably, we found that EMI1’s APC/C inhibitory domain is sub-
stantially natively disordered, thus defining a distinct structural class 
of E3 inhibitor and differing not only from the crystallographically 
characterized MCC but also from several other RING E3 inhibi-
tors2,3,9. Intrinsic disorder enables a small sequence to have multiple 
discrete interaction motifs that mediate binding to multiple sites47. 
Consistent with prior studies, we detected inhibition by isolated 
D-box and EMI1 C-terminal tail peptides23,48. Our data also indi-
cate that the linker and ZBR do not simply serve as spacers between 
the EMI1 D-box and C-terminal tail. We defined, for the first time, 
the linker as an effector of EMI1 function and identified surfaces on the 
linker and ZBR important for inhibiting APC/C. Each element is weak 
on its own, and the combination of the multiple motifs is required for 
maximal inhibition (Fig. 7).
The structural data provide a rationale for many previously 
described features of EMI1 regulation. In addition to inhibition by 
the C-terminal domain22,23, EMI1 also plays a role in localizing a frac-
tion of APC/C to spindle poles18. EM structures reveal that EMI1’s 
N-terminal domain, which binds NuMA–dynein–dynactin to medi-
ate localization, is exposed on the surface and available for interac-
tion without disrupting contacts anchoring the C-terminal domain 
to APC/CCDH1 (Supplementary Fig. 2d). Ultimately, cell-cycle pro-
gression requires APC/C’s liberation from EMI1. The exterior loca-
tion of EMI1’s N-terminal domain also explains how this region can 
be phosphorylated and ubiquitinated to signal EMI1 degradation 
before nuclear envelope breakdown14,20. Human EMI1’s C-terminal 
domain is also blocked from APC/C binding through mitotic cyclin-
 dependent kinase–mediated phosphorylation49. These sites map to 
the EMI1 D-box and to within 5 Å of a bound zinc and the ZBR sur-
face we identified as required for inhibition (Fig. 5f). It seems likely 
that EMI1’s multisite binding to APC/C would enable the individual 
elements to fluctuate on and off, which would allow phosphorylation, 
in turn diminishing capacity for their rebinding and ultimately lead-
ing to separation from APC/C.
Although mechanisms by which intrinsic disorder can modulate 
protein function are only beginning to emerge, it is likely that many 
small, substantially intrinsically disordered domains utilize several 
elements to dynamically regulate multiple functionalities of massive 
molecular machines many times their size. As 30% of the human 
proteome is estimated to be natively unstructured25, we anticipate 
that future studies will reveal other forms of E3-ligase regulation that 
depend on specialized features established by protein disorder.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. APC/CCDH1–EMI1–SKP1, EMD-2354; 
APC/CCDH1–EMI1DLZT, EMD-2353; EMI1ZT, 2M6N.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Protein purification. EMI1 variants correspond to: EMI1NFDL, residues 1–363; 
EMI1FDLZT, residues 236–447; EMI1DLZT, residues 305–447; EMI1ZT, residues 
363–447; EMI1NFDLZ, residues 1–432. EMI1, ubiquitin variants, cycB-NT* and 
UbcycB-NT* were expressed as GST fusions, either from pGEX4T1 or pFastbac-
GST modified to contain a TEV proteolytic site, and were purified by glutathione 
affinity chromatography, followed by His-TEV treatment. EMI1 and EMI1NFDL 
were expressed in High Five cells. All other EMI1 variants were expressed in 
Escherichia coli BL21-Gold cells. All EMI1 variants containing an F-box were 
co-purified with SKP1. EMI1 wild-type and its variants were purified by ion 
exchange chromatography before sizing. GST-cycB-NT* and UbcycB-NT* 
were expressed in High Five cells treated with His-TEV, with GST and His-TEV 
removal by glutathione and nickel affinity chromatography. After sizing, 
cycB-NT* and UbcycB-NT* were FlAsH labeled using a C-terminal tetra-cysteine 
site. Other proteins were described previously37.
APC/CCDH1–EMI1 purification for electron microscopy. HeLa cells were 
grown in DMEM including 10% FBS (Invitrogen), 2 mM l-glutamine and 
100 µg ml−1 penicillin/streptomycin (both from Sigma) and plated on 245 × 
245–cm tissue culture dishes (NUNC). Cell extracts were prepared by lysis of 
frozen log-phase HeLa cells in extract buffer (20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 2 mM EDTA, 10% (v/v) glycerol, 0.1% (w/v) octyl-β-d-glucopyranoside) 
using a Dounce homogenizer followed by centrifugation. APC/C was immuno-
precipitated from the soluble fraction by incubation with an APC3 polyclo-
nal peptide antibody (produced in rabbit) cross-linked to Affi-prep protein A 
beads from Bio-Rad at 1.33 µg per 1 µl beads39. Beads were washed four times 
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 0.1% (v/v) octyl-
β-d-glucopyranoside), and the APC/CCDH1–EMI1 complexes were reconstituted 
in vitro by mixing 3.5 µM PreScission-cleaved CDH1 and 150 nM EMI1–SKP1 
with APC/C-bound APC3 antibody beads in binding buffer (20 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 0.1% (v/v) octyl-β-d-glucopyranoside, 4 mg ml−1 BSA. 
After a 1-h incubation, the beads were washed four times, and APC/C complexes 
were recovered by elution with antigenic peptides. APC/CCDH1–FlagEMI1 com-
plexes were enriched by re-immunoprecipitation experiments using anti-Flag M2 
Agarose (Sigma) and subsequent elution with antigenic peptides. APC/C speci-
mens were subjected to GraFix to further purify and stabilize the complexes.
Electron microscopy. Purified APC/CCDH1–EMI1 complexes were adsorbed to 
a thin film of carbon and then transferred to an electron microscopic grid covered 
with a perforated carbon film. The bound APC/C particles were stained with 2% 
(w/v) uranyl formate, blotted and air-dried for ~1 min at room temperature. Images 
were recorded at a magnification of 119,000× or 155,000× on a 4k × 4k CCD 
camera (TVIPS GmbH) using two-fold pixel binning (2.5 Å or 1.8 Å per pixel) in 
a Philips CM200 FEG electron microscope (Philips/FEI) operated at 160 kV accel-
eration voltage. APC/CCDH1–EMI1 complexes were analyzed as described10.
Generation of recombinant human APC/C. Recombinant human APC/C 
was purified as described, using a C-terminal 2×-Strep tag on APC6 and an 
N-terminal GST tag on APC4 with the following modifications37. MultiBacs 
were constructed using donor plasmids pFL, pIDC, pIDK and pIDS51, except 
the p10 baculoviral promoter was replaced with the polyhedron promoter and 
an additional polyadenylation site (SV40). Three MultiBacs were generated by 
Cre recombination of (i) pIDS CDC26/APC6-2xStrep-tagII, pFL APC11/APC2, 
pIDK APC10/APC5 and pIDC APC16/APC13; (ii) pIDC APC15/APC7 and 
pIDK APC8; and (iii) pFb APC1 with a loxP site from pIDC and pIDS APC3. 
GST-APC4 was expressed from a separate virus.
Enzyme assays. Proteins were purified in 20 mM Tris pH 7.6, 150 mM NaCl, 
1 mM DTT. Ubiquitination assays were performed by combining two inde-
pendent mixtures. One contained APC/C, 5 mM MgCl2, 5 mM ATP, 0.25 mg 
mL−1 BSA, 1 µM CDH1, EMI1 and 100 nM UBA1. APC/C was incubated with 
CDH1 on ice for at least 30 min. Where included, EMI1 was added for 1 h to 
form APC/CCDH1–EMI1 complexes. The second mixture contained E2, 125 µM 
bovine ubiquitin (Sigma) and substrate. Both mixtures were made on ice and 
equilibrated to room temperature before mixing. This combination prevents E2 
autoubiquitination and allows the APC/CCDH1–EMI1 complex to bind without 
competition by either E2 or substrate.
To determine the ½Vmax CDH1 concentration and the Kmapp values for the 
E2s and substrates, the reactions were followed over time and the product bands 
were quantitated based on the FlAsH label on cycB-NT* or UbcycB-NT* or on 
fluorescein on Ub* using a PhosphorImager (Typhoon 9200) to determine the 
initial velocities. For CDH1-dependent reactions, CDH1-independent products 
were subtracted as background. For APC-dependent CDH1-independent reac-
tions, APC/C-independent products were subtracted as background. To deter-
mine the Kiapp of wild-type EMI1 and variants, assay conditions that satisfy the 
requirements to be in the initial velocity were used so that a single time point 
could be used to determine the enzyme’s initial velocity at each EMI1 concentra-
tion. Thus, to determine the Kiapp values of the EMI1 variants, concentrations of 
5 nM APC/C, 900 nM UBCH10, 600 nM UBE2S, 120 nM cycB-NT* and 120 nM 
UbcycB-NT* were used. Reactions with the substrate cycB-NT* and UBCH10 
were performed for 4 min, with the substrate UbcycB-NT* and the E2 UBCH10 
for 4 min and with the substrate UbcycB-NT* and the E2 UBE2S for 2.5 min. 
The ½Vmax and Km values were determined by fitting the initial velocities to a 
hyperbolic curve/Michaelis-Menten, v = Vmax[X]/(Km +[X]), equation, where X 
is either the CDH1, UBCH10, UBE2S or substrate concentration.
Due to the tight binding nature of EMI1, Kiapp values were determined by 
method of Morrison40. The Morrison quadratic function accounts for both 
the depletion of enzyme and inhibitor. Kiapp values were determined by fitting 
the initial velocities to the Morrison tight binding equation (equation (1) using 
GraphPad Prism 6 software),
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where Efree is the concentration of free enzyme determined by the residual 
APC/CCDH1 activity against the activity and concentration of the uninhibited 
APC/CCDH1 activity, [E0] is the total enzyme concentration and [I0] is the total 
inhibitor concentration. Simulations of theoretical Kiapp curves provided us with 
an upper limit of 2.5 nM for Kiapp values for the tight-binding versions of EMI1 
(Supplementary Fig. 5d).
The CDH1, D-box substrate–independent Ub-chain formation assays were 
performed in the same conditions except the acceptor substrate was Ub fluores-
cein (Ub*) G75S-G76S-C77 with an additional C-terminal cysteine that prevents 
its utilization as a Ub donor. Experiments with APC/C in the absence of CDH1, 
with either UbcycB-NT* or Ub* as the substrates, were performed with UBE2S 
for 10 min.
Qualitative assays probing function of ZBR (30 nM EMI1) and linker (30 nM 
EMI1 in Fig. 4; 300 nM and 1 µM in Supplementary Fig. 6) were performed 
as described above except with concentrations of 13 nM APC/C, 10 nM UBA1, 
190 nM UBCH10, 190 nM UBE2s, 20 nM cycB-NT* or 50 nM UbcycB-NT*. 
These reactions were quenched at 12 min.
NMR. NMR spectroscopy. NMR experiments were measured on either a Bruker 
600 or 800 MHz spectrometer equipped with a 1H and 13C detect, TCI triple-
resonance cryogenic probe using standard Bruker pulse programs. 15N-1H HSQC 
spectra were collected at 25 °C. 1H, 13C and 15N backbone resonances were 
assigned using standard triple-resonance experiments, such as HNCA, HNCACB 
and CBCA(CO)NH. The side-chain 1H resonances were assigned using (H)CCH-
TOCSY and H(CCCO)NH experiments. Aromatic side-chain assignments 
were obtained with two-dimensional [13C, 1H]-HSQC and three-dimensional 
13C-resolved aromatic [1H, 1H]-NOESY experiments. Distance constraints for 
the structure calculation were derived from three-dimensional 13C-aliphatic, 
13C-aromatic and 15N-resolved [1H, 1H]-NOESY spectra recorded with a mixing 
time of 100 ms. 1H chemical shifts were referenced with respect to DSS measured 
in the same buffer, whereas 13C and 15N chemical shifts were referenced indirectly 
with respect to the DSS shift. Spectra were processed using Topspin software and 
analyzed using the computer-aided resonance software CARA52. Heteronuclear 
15N {1H} NOEs for EMI1DLZT were measured using a 5 s irradiation period 
and 2 s relaxation delay (NOE) or a 7 s relaxation delay (no NOE) on the 13C, 
15N-labeled sample used for structure calculation.
NMR structure calculations. Structures were determined using a combination 
of manually assigned NOEs and automatic NOE assignment using the program 
CYANA53. Approximately 931 meaningful distance restraints, 38 angle restraints 
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and 32 hydrogen bond restraints based on exchange cross-peaks with water in the 
15N-NOESY spectrum were used in the structure calculation of EMI1ZT (Table 2). 
Seven iterations of refinement for 100 structures per cycle were completed after 
proper distance calibrations. After the initial fold of the protein was determined, 
a CYANA amino acid library using a modified zinc-ligated cysteine residue was 
used to incorporate the two zinc ions into the structures.
Generation of metal-free EMI1ZT and zinc reconstitution. 15N-labeled EMI1ZT 
was incubated in 10 mM sodium phosphate (pH 6.5), 50 mM NaCl, 1 mM DTT 
and 20 mM EDTA and then dialyzed against 10 mM sodium phosphate (pH 6.5), 
50 mM NaCl, 1 mM DTT. Unfolding was confirmed by measuring one- and 
two-dimensional 1H-15N HSQC spectra post-dialysis. Six rounds of dialysis 
resulted in removal of EDTA. Dialysis against 10 mM sodium phosphate 
(pH 6.5), 50 mM NaCl, 1 mM DTT, 200 µM ZnSO4 restored zinc.
51. Bieniossek, C., Richmond, T.J. & Berger, I. MultiBac: multigene baculovirus-based 
eukaryotic protein complex production. Curr. Protoc. Protein Sci. 51, 5.20 (2008).
52. Keller, R.L.J. The computer aided resonance assignment tutorial. 〈http://cara.nmr-
software.org/downloads/3-85600-112-3.pdf〉 (CANTINA Verlag, Zurich, 2004).
53. Güntert, P., Mumenthaler, C. & Wuthrich, K. Torsion angle dynamics for NMR 
structure calculation with the new program DYANA. J. Mol. Biol. 273, 283–298 
(1997).
54. Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. TALOS+: a hybrid method for 
predicting protein backbone torsion angles from NMR chemical shifts. J. Biomol. 
NMR 44, 213–223 (2009).
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